VRTX

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes specialty medicines for serious genetic and metabolic diseases. Its core business centers on cystic fibrosis, where it markets a suite of CFTR‑modulating therapies that treat the majority of patients, and it has expanded into gene‑editing treatments for sickle cell disease and beta thalassemia as well as programs in acute pain, kidney disease and other rare disorders. The company operates within the biotech/pharmaceutical sector and is recognized for its dominant market position in cystic fibrosis and for being a pioneer in bringing the first approved CRISPR‑based therapy to market.